Neurodegenerative disease risk among former international rugby union players Supplementary figures and tables


Supplementary Table 1: ICD-9 and ICD-10 codes for outcomes assessed.

	ICD-9	ICD-10
Neurodegenerative disease	290.0 to .4; 294.1 & .2; 331.0 to .2 & .6 to .9; 332; 335.2	F01 to F03; G12.2; G20; G21; G23.1 to .3, .8 & .9; G30; G31
Dementia, not otherwise specified	290.0 to .4; 294.1 & .2; 331.0 to .2 & .6 to .9;	F01 to F03; G23.1 to .3; G30; G31
Motor neuron disease/ Amyotrophic lateral sclerosis	335.2	G12.2
Parkinson's disease	332	G20; G21; G23.8 & .9
Cardiovascular disease	390 to 459	100 to 199
Respiratory disease	460 to 519	J00 to J99
Cancer	140 to 239	C00 to D49

Supplementary Table 2: British National Formulary (BNF) subsections and drugs assessed in the analysis of neurodegenerative disease related prescriptions.

BNF section	Drugs
4.9.1	Apomorphine hydrochloride Apomorphine hydrochloride hemihydrate Carbidopa Co-beneldopa (Benserazide/levodopa) Co-careldopa (Carbidopa/levodopa) Entacapone Levodopa Levodopa/carbidopa/entacapone Opicapone Rasagiline mesylate Safinamide Selegiline hydrochloride Tolcapone
4.9.2	Orphenadrine hydrochloride Trihexyphenidyl hydrochloride
4.9.3	Riluzole
4.11	Donepezil hydrochloride Galantamine Idebenone Memantine hydrochloride Rivastigmine

Supplementary Figure 1: Flow diagram of the creation of the final former international rugby player and matched general population comparison group.



Final cohort: 412 former international rugby players